Jennison Associates
FATE icon

Jennison Associates’s Fate Therapeutics FATE Stock Holding History

Jennison Associates’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-25,000
Closed -$2.27M – 690
2020
Q4 		$2.27M Buy
+25,000
New +$1.55M ﹤0.01% 501

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates's FATE Position: Q4 2021 in Review

Jennison Associates sold out of Fate Therapeutics (FATE) in Q4 2021, closing a stake of 383,714 shares — an estimated $22.7M sold.

Jennison Associates first reported a position in FATE in Q3 2018 and held it in 13 quarters. The position peaked at $70.5M in Q4 2020. 250 funds tracked by Wall St. Rank hold FATE as of Q4 2021.

  • Jennison Associates reported no remaining Fate Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Jennison Associates sold 383,714 Fate Therapeutics shares in Q4 2021, an estimated $22.7M.
  • Jennison Associates first reported a position in Fate Therapeutics in Q3 2018 and held it in 13 quarters.
  • Jennison Associates's Fate Therapeutics position peaked at $70.5M in Q4 2020.
  • 250 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2021.

Based on Jennison Associates's 13F filing for Q4 2021, filed 8 Feb 2022.